Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma is a research paper published in Translational Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 24 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Cancer Prevention and Research Institute of Texas
Grant: RP 150032
Cancer Prevention and Research Institute of Texas
Grant: RP 170169
Cancer Prevention and Research Institute of Texas
Grant: RP140469
Cancer Prevention and Research Institute of Texas
Grant: RP180177
National Institutes of Health
Grant: 1-UO1-CA217613
National Institutes of Health
Grant: RO1 CA185402
National Institute of Neurological Disorders and Stroke
Grant: RO1 NS080963
Welch Foundation
Grant: H-Q-0042
NINDS NIH HHS
Grant: R01 NS080963
NCI NIH HHS
Grant: U01 CA217613
NCI NIH HHS
Grant: R01 CA185402
National Institutes of Health
Grant: 5R01NS080963-02
Chemical Probes Targeting Gliomas with IDH Mutation
National Institutes of Health
Grant: 1R01CA185402-01
(PQD-5) Patient derived orthotopic xenograft models for drug response prediction
National Institutes of Health
Grant: 5U01CA217613-05
Matching panels of in vivo and in vitro model system of pediatric brain tumors
Cincinnati Children’s Research Foundation
FWCI
3.96
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals